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Abstract. The tachykinin mouse HK-1, expressed by 
the mouse Tac4 gene, produces either analgesia or 
nociception, interacting with the NK1 receptor.  
TAC4 precursor processing is not identical to the 
processing of the TAC1 precursor, for the release of 
substance P (amidated undecapeptide). In an effort to 
characterize the murine TAC4 precursor processing, 
we developed anti-tachykinin specific antibodies for 
the isolation of tachykinins. Using MALDI-ToF, we 
identified mouse HK-1 as an amidated decapeptide 
expressed in murine brain and periphery. 
Furthermore, we interestingly observed an additional 
mass peak corresponding to acetylated mouse HK-1 
and this post-translational modification is brain 
specific, not detected in the periphery. We suggest 
that this N-terminal acetylation of the peptide 
provides greater potency for ligand-receptor 
interactions during neural cell signaling.  
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Tachykinins as a vast family of highly conserved 
peptides share the signature C-terminal motif 
FXGLM-NH2 (where X in mammals is F, Y, V; in 
fish, H, I, and in ascidians T) (1, 2, 3). The 
tachykinin mHK-1 discovered as an autocrine factor 
during pro-B lymphocyte differentiation introduced 
the group of endokinins (4) which also comprises 
human HK-1 (5), and its extended forms EKA and 
EKB (6) or truncated forms such as the tachykinin 
hHK-1 (4-11) (7). Tachykinins act as agonists on the 
three mammalian tachykinin receptors NK1, NK2, 
NK3 with different potencies (5, 8). The hydrophobic 
C-terminal tachykinin motif activates the receptor, 
and the C-terminal amidation is crucial for activation 
(9, 10). Binding studies on the NK1 receptor showed 
mHK-1 as having similar binding affinity on this 
receptor as SP (11, 12, 13) and a similar affinity for 
each of the mouse, rat and human NK1 receptors (5, 
7, 14).  
The opposite effects of mHK-1 and SP in 
thermal hyperalgesia, have suggested the two 
peptides could bind to different subtypes of NK1 
receptor (15, 16). The activation of NK1 receptor is 
related to the release of endogenous 
proopiomelanocortin, as well as the increased 
expression levels of the μ-opioid receptor in 
analgesia (17). Moreover, it was reported that the N- 
and C-terminal fragments of the mHK-1 elicited 
opposite biological effects (i.e. inhibition or 
induction of pruritus) when administered in rats, 
through the activation of the NK1 receptor (18). 
Recent evidence showed anxiolytic and anti-
depressant-like actions for mHK-1 (19). The 
nociceptive behaviors induced by mHK-1 were 
inhibited by NMDA receptor antagonists. A 
significant increase in glutamate levels was observed, 
which was reduced by co-administration with 
NMDA receptor antagonists, suggesting that mHK-1-
induced nociceptive effects may be mediated by the 
NMDA receptor (20). The Tachykinin receptor-1 
(TACR1) gene was found among the neurotoxicity-
associated genes in brain tissue that were 
significantly modulated after irradiation, suggesting 
that catenin-β1 and tumor suppressor-related 
transcription regulation are significantly activated by 
radiation and/or minocycline suggesting minocycline 
as a potential neuroprotectant against radiation-
induced damage (21). Moreover, the TACR3 was 
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shown highly expressed in oral squamous cell 
carcinoma suggesting TAC3 as released by the 
peripheral sensory nerves which may act in tumor 
cells and that TACR3 signaling may, in turn, 
contribute to tumor progression (22). 
In the present study, the characterization of 
mHK-1 sequence and post-translational 
modifications were investigated. The rat TAC4 
precursor comprises mHK-1 flanked by dibasic KR 
cleavage sites, releasing the decapeptide 
SRTRQFYGLM-NH2. Previous studies (4, 7, 8) have 
reported mHK-1 as an undecapeptide suggesting 
precursor processing occurring between the K/R 
residues of the dibasic cleavage site, hence, 
purification and identification of the peptide mass 
was required. Antibodies were raised against EKA/B 
(GKASQFFGLM-NH2) that efficiently recognized 
mHK-1 (SRTRQFYGLM-NH2) and SP, then purified 
and immobilized on Sepharose beads, to produce an 
affinity medium capable of isolating endogenous 
mHK-1 and SP. Captured peptides were separated on 
RP-HPLC and detected using MALDI-ToF. We 
identified mHK-1 as an amidated decapeptide 
expressed in both brain and spleen with an additional 
mass peak corresponding to a brain-specific N-
terminal acetylation. 
 
Materials and Methods 
 
Development of anti-tachykinin antibodies and 
determination of their reactivity to the peptides 
SRTRQFYGLM-NH2 or RPKPQQFFGLM-NH2 with 
antibody-titre curves. All reagents were purchased 
from Sigma-Aldrich unless otherwise stated. 
Tachykinin antisera were raised in sheep as described 
previously (5). Two animals were inoculated with the 
antigen EKA/B coupled to BSA (antisera annotated 
as BO14 and BO16). Plates (Nunc Immobilizer™ 
Amino) were coated with 200 ng of synthetic 
peptide. Dilutions of the ovine antisera in albumin-
phosphate buffer (0.04 M Na2HPO4, 0.01 M 
NaH2PO4, and 0.5% (w/v) BSA) were produced and 
dispensed in duplicate into the wells. After 
incubating at room temperature, the wells were 
washed with buffer (0.9% (w/v) NaCl, 0.01% (v/v) 
Triton X-100) three times. A 1/5000 dilution of 
donkey anti-sheep IgG-alkaline phosphatase 
conjugate in albumin-phosphate buffer was added, 
incubated for two hours at room temperature and was 
removed. The substrate p-nitrophenyl phosphate was 
used for the detection of immunoreactivity. Plates 
were read at 450 nm, and the data were represented 
as absorbance units. 
 
Purification of anti-tachykinin antibodies 
recognizing SRTRQFYGLM-NH2 and SP. Cyanogen 
bromide-activated Sepharose beads (1 g) were 
swollen into a 3.5 ml gel, washed with 1 mM HCl, 
and then suspended in coupling buffer (0.1 M 
NaHCO3, 0.5 M NaCl, and 0.5% (v/v) Tween 20, pH 
~9). Synthetic SRTRQFYGLM-NH2 (0.5 mg; custom 
made by Designer Biosciences, Cambridge) and SP 
(0.5 mg) were dissolved in 1 ml of the coupling 
buffer and added into the Sepharose gel (incubated 
overnight at room temperature). The unbound 
reactive sites on the Sepharose beads were blocked 
with glycine (0.2 M, pH ~8), and the gel was loaded 
onto an Econo-column fitted with a flow adaptor and 
30 cm of silicon tubing (BioRad). Each ovine 
antiserum (50 ml) containing a protease inhibitor 
mixture (Roche), 0.18 g EDTA disodium and 2% 
(w/v) NaN3 was loaded onto the column. Three 
columns volume of washing buffer (PBS containing 
0.01% (v/v) Tween-20) were applied. Two columns 
volume of elution buffer (0.1 M citric acid pH ~2.5) 
were added and incubated for 5 min; the eluted 
antibodies (6 ml) were immediately neutralized.   
 
Immobilization of anti-tachykinin antibodies on 
cyanogen bromide-activated Sepharose beads. 
Cyanogen bromide-activated Sepharose beads (1 g) 
were activated and washed with 1 mM HCl and then 
suspended in coupling buffer. The immunopurified 
anti-tachykinin antibodies were diluted in coupling 
buffer and added into the Sepharose gel, incubated 
overnight at room temperature. Unbound reactive 
sites were blocked; the blocking agent was removed, 
and the anti-tachykinin antibody-Sepharose 
conjugates were stored in 5 ml of storage buffer (1 M 
NaCl with 0.02% (w/v) NaN3 and 1 mM EDTA 
disodium) at 4 ºC. 
 
Isolation of tachykinins by immunoaffinity 
purification. One rat brain was homogenized using a 
10ml syringe. Two rat spleens were homogenized 
using a mortar and pestle while keeping tissues 
frozen in liquid nitrogen. Each homogenized tissue 
was suspended in 1 ml of extraction buffer (Bennett’s 
solution consisting of, 1 M HCl containing 5% (v/v) 
formic acid, 1% (w/v) NaCl and 1% (v/v) TFA) and 
incubated overnight at 4 ºC. The mixture was 
centrifuged at 7500 x g for 15 min and 1 ml of 
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peptide extract was recovered. The peptide extract 
was diluted in 9 ml of 0.1% (v/v) aqueous TFA. The 
diluted peptide extract was loaded onto a C18 Sep-
Pak cartridge (Waters) previously primed with 
methanol and equilibrated with 0.1% (v/v) TFA). 
Peptides were eluted with 1 ml of 60% (v/v) 
acetonitrile with 0.1% (v/v) TFA, neutralized with 1 
M TRIS pH ~10 and concentrated under a continuous 
flow of N2. The peptide extract was incubated with 
60 µl of anti-tachykinin antibody-Sepharose beads 
suspended in binding buffer (10 mM EDTA 
disodium, 0.01% (w/v) octyl β-D-glucopyranoside, 
0.02% (w/v) NaN3, and protease inhibitors mixture in 
PBS). The final volume of the reaction was 500 µl, 
which was incubated at room temperature overnight. 
Next, the beads were washed extensively with 
working buffer and peptides 
were eluted incubating with 60 µl of 0.5% (w/v) TFA 
and centrifuging at 700 x g for 5 min.  
 
Separation of enriched peptides on RP-HPLC and 
detection on MALDI-ToF. RP-HPLC was performed 
using a Waters 600E system controller (Millipore) 
and a Waters 486 Tunable UV absorbance detector 
system, with a reversed phase C18 column (Vydac 
218TP54). An aliquot of the rat brain and spleen 
immunoaffinity eluents was injected into the system, 
and peptides were eluted with a linear gradient 
starting at 10% acetonitrile with 0.04% (v/v) TFA, 
taken to 40% over 30 min, and kept constant at 100% 
for 10 min. The flow rate was set at 0.5 ml/min and 
absorbance at 205 nm. Fractions of 250 µl were 
manually collected, and organic solvents were 
removed under a constant N2 flow. Each 20 µl 
fraction was further concentrated with a ZipTipµ-C18 
(Millipore) primed with 50% (v/v) methanol with 
0.1% (v/v) TFA and equilibrated with 0.1% (v/v) 
TFA. Peptides were directly spotted, with α-Cyano-
4-hydroxycinnamic acid matrix (Agilent 
Technologies) dissolved in ethanol with 1% (v/v) 
TFA, on an MALDI-ToF plate (ground steel Bruker). 
Peaks were detected using an MALDI-ToF (Bruker 
Autoflex III) instrument with FlexControl software.   
 
Results 
 
Anti-tachykinin antibodies were raised by inoculating 
two sheep with the same antigen i.e. EKA/B 
(GKASQFFGLM-NH2). The anti-sera were capable 
of recognizing the SP and SRTRQFYGLM-NH2 
peptides. Although, tachykinins possess a backbone 
on the FXGLM-NH2 motif and also a charged amide 
group that makes this motif region very 
immunogenic, however, in the present study, a 
different response was observed, between the two 
sheep, with respect to the yielded antibody titres 
against SP and SRTRQFYGLM-NH2 (Figure 1A, B). 
As it appears in Figure 1B, the BO16 antiserum 
showed a substantially higher titre of antibodies 
recognizing SRTRQFYGLM-NH2 and SP as 
compared to the BO14 antiserum and therefore the 
BO16 purified antibodies were immobilized to yield 
an affinity medium.  
A RP-HPLC method was developed for the 
separation of synthetic SRTRQFYGLM-NH2 and SP. 
Figure 2A shows the chromatogram of the synthetic 
SRTRQFYGLM-NH2 with retention time 1402 s and 
Figure 2B shows the chromatogram of the elution of 
synthetic SP with retention time 1706 s. The elution 
fraction and mass of the two peptides was confirmed 
with MALDI-ToF. The sequence SRTRQFYGLM-
NH2 has a singly charged mass [M+H]
+
 1257.652 
a.m.u. The [M+H]
+
 of the SP undecapeptide is 
1347.735 a.m.u.  
 
mHK-1 is a decapeptide with a neuropeptide-specific 
N-terminal acetylation. Endogenous tachykinin 
peptides identified by MALDI-ToF in rat brain and 
spleen and their modifications are shown in Table 1. 
In Figure 3 endogenous mHK-1 in the rat spleen and 
brain is shown. The peak seen at m/z 1257.701 
corresponds to the mHK-1 decapeptide, and the peak 
seen at m/z 1273.697 is the mHK-1-methionine 
sulphoxide (SRTRQFYGLM(S→O)-NH2). In rat 
brain, the additional peak seen at m/z 1299.710 (ΔM 
+42.049 a.m.u) is an acetylated form of mHK-1 (Ac-
SRTRQFYGLM-NH2). The hydroxyl group of the 
serine is most probably acetylated by specific serine 
acetyl-transferases.  
 
The expression of SP in rat brain and spleen. Figure 
4 shows SP detected in both rat brain and spleen. The 
m/z 1347.894 peak corresponds to [M+H]
+
 SP while 
the peak seen at m/z 1363.886 is SP-methionine 
sulphoxide [SP (S→O)]+. Our findings show SP is 
abundantly expressed in the rat brain (acting as a 
neuropeptide) and also SP is expressed in high levels 
in the rat spleen (acting as an autocrine or paracrine 
factor).  
 
Discussion  
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The sequence of the mHK-1 was deduced 
from the nucleotide sequence of the novel cDNA, 
initially named as PPTC and then as Tac4 gene, 
using the updated standardized nomenclature (23) 
and was predicted as an amidated undecapeptide 
RSRTRQFYGLM-NH2 (4). Therefore, a more 
definite characterization of the mHK-1 was required 
i.e. identification of its M.W. and its sequence, as 
well as any post-translational modifications apart 
from the well-established C-terminal amidation. The 
expression of the mHK-1 in brain has not been clear; 
Zhang and colleagues (2000) reported the Tac4 gene 
not to be expressed in mouse brain but rather in 
lymphopoietic cells of the periphery, using a rather 
insensitive Northen blot analysis; later reports, 
showed the expression of the Tac4 gene in the rat 
brain (7, 14, 24).  
Our present study has proven mHK-1 as an 
amidated decapeptide with an a.a. sequence and 
M.W. corresponding to SRTRQFYGLM-NH2 (Figure 
3). This finding is not in agreement with the 
predicted sequence of mHK-1 as RSRTRQFYGLM-
NH2 (mass 1412.75 Da). We have shown the mass of 
the mHK-1 as [M+H]
+
 1257.701 Da same as the 
theoretical (1257.652 Da). The mHK-1 peptide 
(SRTRQFYGLM-NH2) comprises two monobasic 
cleavage sites at the R residues, releasing the 
truncated peptides TRQFYGLM-NH2 (1014.519 Da) 
and QFYGLM-NH2 (757.37 Da). We investigated 
the trypsinisation of synthetic mHK-1 and observed 
the processing of the peptide indeed occurs in vitro in 
both monobasic cleavage sites (data not shown). 
However, the above species were not detected in 
either of the tissues investigated. Both truncated 
peptides would show affinity for the NK1 receptor 
and elicit a biological response as the minimum 
peptide fragment with the ability to show a similar 
biological response on the NK receptors as the 
mature form is the C-terminal hexapeptide (25). 
In the present study, SP was also purified 
from rat brain and rat spleen (Figure 4). This finding 
is well in line with previous reports showing 
expression of the Tac1gene in human and rat brain 
and human spleen (6, 14). Moreover, peptide 
expression studies have detected SP in the brain 
using mass spectrometry (26, 27). Spectra obtained 
from our study showed that SP was detected with 
high abundance in both tissues; however post-
translational modifications were not identified on SP. 
A whole rat brain was used comprising different 
types of cells. Neuronal cells would produce the 
acetylated form of mHK-1, while immune cells the 
non-acetylated form. Further pharmacological 
investigations would elucidate the potency of the 
mHK-1 decapeptide for the NK1 receptor.  
The structure-activity relationship between 
mHK-1 as a decapeptide and SP as an undecapeptide 
may be determined by their binding to their 
respective receptor. In nociception, the cell signaling 
is through G-proteins, therefore we can suppose that 
SP acts on the stimulatory subunits of G-proteins and 
thus increasing the GTPase activity and eventually 
the Ca
2+
 (i), while mHK-1 may act on the inhibitory 
subunits of G-proteins therefore a balance system 
between nociceptors and analgesia may be in place 
(bystable systems).  
Furthermore, in this study we identified 
mHK-1 in the rat brain comprising a post-
translational modification i.e. acetylation of the 
hydroxyl group of the serine residue. Acetylation 
occurs by the enzymes N-acetyltransferases most 
probably in the Golgi apparatus (28, 29). The peak of 
the mHK-1 [M+H]
+
 (1257.661 a.m.u.) and the 
acetylated form of mHK-1 (1299.710 a.m.u.) could 
exist in vivo in a ratio suggesting the existence of an 
acetylation and de-acetylation system controlled by 
specific enzymes i.e. serine N-acetyltransferases and 
de-acetyltransferases. Acetylation is one of the 
signature post-translational modifications of 
neuropeptides and the consensus for the biological 
role of acetylation is greater stability for the peptide 
and potency of the peptide with its receptor (30, 31). 
Acetylation may protect the peptide from degrading 
enzymes e.g. neprilysin and also acetylation 
enhances peptide-receptor interactions (32). The 
TAC4 precursor comprises a signal peptide hence it 
is directed into Golgi apparatus and stored in vesicles 
where acetylation occurs (33). Upon release the 
acetylated mHK-1 activates the NK1 receptor located 
on the metasynaptic membrane. De-acetylases 
present on the metasynaptic membrane de-acetylate 
the peptide, hence, acting as a potential on/off switch 
of the NK1 receptor (molecular switch).  
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Figure 1. Antibody titre curves of two anti-tachykinin antisera BO16 (squares) and BO14 (diamonds). 
(A). Binding of the two antisera with SP. The antibody titre curves obtained with normal sheep serum 
(triangles) were used as a negative control. (B) The antibody titre curves of the same antisera against 
mHK-1.  
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Figure 2. Reversed-phase separation of mHK-1 and SP. (A) Elution profile of synthetic mHK-1 
(SRTRQFYGLM-NH2). Briefly, the peptide was eluted with a gradient of acetonitrile (dashed red 
line). The synthetic peptide eluted in fractions 11 and 12 (grey). Forty fractions were collected and 
the presence of the synthetic mHK-1 was confirmed by MALDI-ToF. The endogenous mHK-1 was 
separated using exactly the same instrument settings. The peptide was detected using MALDI-ToF in 
fraction 11 only (fraction shown in green). (B) The elution profile of synthetic SP, eluted with the 
same instrument settings as for mHK-1. The synthetic SP eluted in fractions 21 and 22 (grey). 
Endogenous SP (captured from rat brain and spleen) eluted in fraction 21 (blue).   
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Figure 3. MALDI-ToF ion spectra of mHK-1. The upper ion spectrum illustrates peaks detected in 
the rat spleen. The peak at m/z 1257.701 is mHK-1, and the peak at m/z 1273.697 is the oxidized 
form of the same peptide. The lower ion spectrum shows peaks detected in rat brain. The peak at m/z 
1299.710 is acetylated mHK-1. A post-translationally modified form of endogenous mHK-1 (m/z 
1299.710) corresponds to the acetylation of the N-terminal serine. 
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Figure 4. MALDI-ToF ion spectra of SP. The upper ion spectrum illustrates peaks detected in the rat 
spleen. The peak at m/z 1347.894 is SP, and the peak at m/z 1363.886 is the form where methionine 
was oxidized (sulphur to sulphoxide). The lower ion spectrum illustrates SP [(S→O)]+ seen at 
1363.894 m/z detected in rat brain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[SP(S→O)]
+
 
[SP (S→O)]+ 
[SP]
+ 
[SP]
+ 
Rat brain 
Rat spleen 
12 
 
Table 1. Tachykinin peptides (mHK-1 and SP) and their modifications identified by MALDI-ToF. 
Mass 
detected
1
 
Peptide Sequence 
ΔM 
(a.m.u.)
2
 
Modification 
1257.701 mHK-1 SRTRQFYGLM-NH2  Unmodified form. 
1273.697 mHK-1 SRTRQFYGLM-NH2 (S→O) 16 
Methionine (sulphur to 
sulphoxide). 
1299.710 mHK-1 Ac-SRTRQFYGLM-NH2 42 
N-terminal acetylation 
of serine residue. 
1347.894 SP RPKPQQFFGLM-NH2  Unmodified form. 
1363.886 SP RPKPQQFFGLM-NH2 (S→O) 16 
Methionine (sulphur to 
sulphoxide). 
1
Mass indicates [M+H]
+
. 
2ΔM, indicates the mass difference from the un-modified form, measured in 
a.m.u. (atomic mass units).  
 
 
 
  
 
 
 
